Lexeo Therapeutics (LXEO) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $228.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | SCTX |
|---|---|---|
| Share price | $2.96 | $12.07 |
| Market cap | $245.05M | $228.58M |
| 1-day change | +0.34% | -8.70% |
| YTD return | -70.19% | — |
| 1-year return | -67.33% | — |
| EPS (TTM) | $-1.13 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-100.00M | — |
| 52-week high | $10.99 | $39.60 |
| 52-week low | $2.55 | $12.00 |
| Distance from 52-week high | -73.07% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +748.31% | +372.25% |
| Average volume | 1.98M | 403.27K |
| Shares outstanding | 82.79M | 18.94M |
| Employees | 68 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
LXEO vs SCTX FAQ
Which is bigger, Lexeo Therapeutics or Scribe Therapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $228.58M for Scribe Therapeutics (SCTX).
Are Lexeo Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.